Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "GLUT1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glucose transporter 1 (or GLUT1), also known as solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1), is a uniporter protein that in humans is encoded by the SLC2A1 gene. GLUT1 facilitates the transport of glucose across the plasma membranes of mammalian cells. This gene encodes a major glucose transporter in the mammalian blood-brain barrier. The encoded protein is found primarily in the cell membrane and on the cell surface, where it can also function as a receptor for human T-cell leukemia virus (HTLV) I and II. Mutations in this gene can cause GLUT1 deficiency syndrome 1, GLUT1 deficiency syndrome 2, idiopathic generalized epilepsy 12, dystonia 9, and stomatin-deficient cryohydrocytosis.
Triheptanoin for the treatment of glucose transport 1 deficiency
ActiveUS20140221482A1Restores mitochondrial energy functionRestores net biosynthesisBiocideNervous disorderTriheptanoinGlucose polymers
Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
Owner:BAYLOR RES INST +1
Triheptanoin for the treatment of glucose transport 1 deficiency
Owner:BAYLOR RES INST +1
Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders
This invention relates to methods of using the monoglyceride of acetoacetate and metabolic precursors for the treatment, prevention, inhibition or alleviation of neurological diseases associated with neuronal hypometabolism, such as Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, age associated memory impairment (AAMI), Traumatic Brain Injury (TBI), Huntington's disease and many others.
Owner:CERECIN INC
A method of screening for a compound capable of stimulating glucose transport into brown and/or brite adipocytes of a mammal, a kit for use in such a method
InactiveUS20170153225A1Lower requirementReduce morbidityDisease diagnosisBiological testingMammalBrite Adipocytes
A method of screening for a candidate compound for use in the treatment of a condition involving dysregulation of metabolism in a mammal by identifying a compound capable of stimulating de novo synthesis of GLUT1 (Glucose transporter 1) in brown and / or brite adipocytes of the mammal and / or capable of stimulating translocation of GLUT1 in brown and / or brite adipocytes of the mammal. A kit for use in the method.
Owner:ATROGI
Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
Owner:CERECIN INC
Preparation and application of breast cancer targeted liposome modified by biotin and glucose
InactiveCN110840844AImprove tumor targetingAvoid damageOrganic active ingredientsPharmaceutical non-active ingredientsCancer researchBiotin transporter
The invention discloses a novel lipid material for realizing the delivery of a breast cancer targeted drug. The novel lipid material takes lysine as a connecting group and is connected with a cholesteric part, a biotin part and a glucose part. The affinity between biotin and glucose in the novel lipid material and biotin transporter (SMVT) and glucose transporter (GLUT1) can be utilized to realizethe double targeting function to breast cancer and play a stronger breast cancer targeting therapeutic role, wherein the biotin transporter (SMVT) and the glucose transporter (GLUT1) are highly expressed on the surface of breast cancer cells. The novel lipid material can be used in different dosage forms comprising liposomes, nanoparticles, micelles and the like, and the prepared paclitaxel-loaded liposome has obvious breast cancer targeting property and a wide application prospect.
Owner:SICHUAN UNIV
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
InactiveUS20180042991A1Nervous disorderCell receptors/surface-antigens/surface-determinantsMammalViral vector
The present invention relates to recombinant Glut1 adeno-associated viral vector (rAAV) constructs and related methods for restoring Glut1 expression in Glut1 deficient mammals. In certain embodiments, the rAAV further comprises a chicken β-actin promoter wherein the rAAV is capable of crossing the blood-brain barrier (BBB). In certain embodiments, the present invention relates to a composition comprising any of the recombinant AAV's described herein. In certain embodiments, the present invention relates to a kit comprising a container housing comprising the composition described herein. In certain embodiments, the present invention relates to methods of restoring Glut1 transport in the BBB of a subject, comprising administering to the subject an effective amount of any of the recombinant AAV vectors described herein. In certain embodiments, the present invention relates to a method of treating Glut1 deficiency syndrome in a subject in need thereof.
Owner:UNIV OF MASSACHUSETTS +1
Use of saccharomyces cerevisiae ERG4 mutants for expressing mammalian glucose transporters
The invention relates to yeast strains in which a human GLUT4 transporter or a human GLUT1 transporter can be functionally expressed and in particular GLUT4 transport proteins which can be particularly easily functionally expressed in yeast strains.
Owner:SANOFI AVENTIS DEUT GMBH
Use of Saccharomyces cerevisiae erg4 mutants for expressing mammalian glucose transporters
The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.
Owner:SANOFI AVENTIS DEUT GMBH
Preparation and application of glucose and triphenylphosphonium modified brain tumor targeting liposome
ActiveCN113230417APharmaceutical non-active ingredientsAntineoplastic agentsSide effectTumor targeting
The invention discloses preparation and application of glucose and triphenylphosphonium co-modified reduction-sensitive brain tumor targeting lipidosome, which are used for realizing efficient transmission of brain tumor targeting drugs. The novel liposome is jointly modified by glucose and triphenylphosphonium, can respectively recognize a glucose transporter GLUT1 highly expressed on the surface of a blood brain barrier and a brain tumor cell, and can generate electrostatic interaction with mitochondria in the tumor cell, and from two levels of cells and organelles, the multi-targeting function on blood-brain barriers, tumor tissues and mitochondria is realized, and a stronger brain tumor targeting treatment effect is achieved. The novel liposome can be used for combined entrapment of chemotherapy drugs and chemotherapy sensitizers acting on mitochondria, is used for synergistic treatment of brain tumors, has more accurate brain tumor targeting, can improve chemotherapy effects and reduce toxic and side effects, and has a wide application prospect.
Owner:SICHUAN UNIV
Preparation method and medical application of benzisothiazole and benzothiophene
ActiveCN113264900AExcellent agonistic activityHigh activityOrganic active ingredientsOrganic chemistryDyslipidemiaPharmacology
The invention discloses a preparation method and medical application of benzisothiazole and benzothiophene, and telates to the field of pharmaceutical chemistry. According to the invention, benzisothiazole and benzothiophene are the first type of HIF-2 agonists; compared with a compound M1001 found by the applicant in the earlier stage, the invention has better HIF-2 agonist activity, and has remarkable enhancement activity on expression of mRNA and protein of EPO, VGEF, Glut1, NDRG1 and the like at the downstream of HIF-2, so that the invention can be used for preparing drugs for treating and / or preventing chronic kidney diseases / chronic renal anemia, dyslipidemia and high cholesterol caused by abnormal expression of HIF-2; and the method has a good industrialization prospect.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1
Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism
InactiveUS20110003767A1Lower metabolismLoss of cognitive functionBiocideNervous disorderHuntingtons choreaMild cognitive impairment (MCI)
This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and / or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, Huntington's disease and many others.
Owner:CERECIN INC +1
Slc2a1 lncrna as a biologic and related treatments and methods
PendingUS20210222167A1Metabolism disorderViral/bacteriophage medical ingredientsDiseaseDiabetes mellitus
The present invention relates to a novel antisense transcript to the human SLC2A1 (Glut1) gene, variants and fragments thereof. This antisense transcript can be used to modulate Glut1 expression and serve to restore Glut1, and as a therapeutic for treating or preventing Glut 1 deficiency syndrome, or other Glut1 related conditions including certain cancers, diabetes, Alzheimer's disease, and retinitis pigmentosa.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
InactiveUS20130143753A1High riskNucleotide librariesMicrobiological testing/measurementCTGFLower risk
The present invention relates to biomarkers allowing predicting breast tumor and solid tumor outcome using hypoxia related genes. More specifically, the present invention relates to a method for predicting the survival of a patient suffering from cancer, said method comprising the steps of (a) measuring the expression of at least five genes selected from the group consisting of GLUT1, PGK1, LDHA, ENO1, CAIX, NHERF1, TPI, AMF / GPI, VEGFA, TGFB3, ENG, LEP, EDN1, MDR1, AK3, MXR1, TGM2, CDH1, MMP2, CK1 9, VIM, CXCR4, UPAR, CATHD, CTGF, C0X2, MET, IGF-2, CCND1, EPO, NDRG1, BNIP3, NIX, ETS1, PHD2, TWIST1, DEC1, SNAH, CEBPA, CITED2, F0X03A, NUR77, BRCA1, PTEN, VHL and ERBB2 in a biological sample of said patient, and (b) analyzing the expression values to generate a risk score of relapse, wherein a risk score superior or equal to three is indicative of high risk of relapse and a risk score inferior or equal to two is indicative of a low risk of relapse. In particular the following genes: EPO, ETS1, ENO1, PGK1, LDHA, TPI and optionally VEGFA were significantly over-expressed in patients with relapse.
Owner:ADELBIO +2
Methods for treating diabetes
InactiveUS20060121035A1Peptide/protein ingredientsGenetic material ingredientsDiabetes mellitusHexose Transporter
Methods for treating diabetes by administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta (TGF-β) superfamily of structurally-related growth factors (e.g., GDF-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as GLUT4 and GLUT1, in a subject by administering an inhibitor of GDF-8. Also disclosed are methods for increasing glucose uptake by cells in a subject, by administering an inhibitor of GDF-8.
Owner:STRASSMANN GIDEON +2
A kind of camptothecin glycoconjugate and its preparation method and application
ActiveCN110423259BHas antitumor effectAchieve anti-tumor effectEsterified saccharide compoundsOrganic active ingredientsRed blood cellGlycoconjugate
Owner:GUANGDONG UNIV OF TECH
Polyselenoamino acid amphiphilic block copolymer targeting glucose transporter 1 as well as preparation method and application thereof
PendingCN113698595ASmall toxicityReduce dosing frequencyNervous disorderMetabolism disorderDiseaseTherapeutic effect
The invention relates to a polyselenoamino acid amphiphilic block copolymer targeting glucose transporter 1 as well as a preparation method and application of the polyselenoamino acid amphiphilic block copolymer. The copolymer has a structure as shown in a formula (I). The copolymer can be self-assembled into different forms of nano-drug carriers (such as nano-spherical micelles, nano-rod micelles and nano-vesicles) in different environments. The targeted GLUT1 and nano-drug carrier can be used for research and development of various drugs, can load drug molecules to prepare a sustained-release and controlled-release targeted drug delivery system, and can directionally deliver the drug molecules to diseased regions, so that the drug administration frequency is reduced, the treatment effect is improved and the like. According to the invention, the copolymer has the advantages of common amino acid copolymers, has various biological functions of selenium, also has specificity of targeting GLUT1, and is suitable for drug carrier research, development and clinical application of various drugs for various diseases related to GLUT1 abnormity.
Owner:SHENZHEN UNIV
Application of GLUT1 as prevention and/or treatment target of hyperpigmented villus nodular synovitis
PendingCN113308528AInhibit glycolysisPromote growthOrganic active ingredientsAntipyreticSynovial CellTreatment targets
The invention relates to the technical field of biological medicine, and concretely relates to application of GLUT1 as a prevention and / or treatment target of hyperpigmentation villus nodular synovitis. The applicant discovers that the GLUT1 is highly expressed in the synovial cells of the hyperpigmented villus nodular synovitis for the first time, the invention provides the application of the GLUT1 as the prevention and / or treatment target of the hyperpigmented villus nodular synovitis, and the GLUT1 can be used as a drug target for screening drugs for preventing and / or treating the hyperpigmented villus nodular synovitis, and a novel screening method and a novel research and development thought are provided for the drugs for preventing and / or treating hyperpigmentation villus nodular synovitis.
Owner:JINAN UNIVERSITY
Glucose transport inhibitors
Owner:BAYER PHARMA AG
Glucose transport inhibitors
InactiveUS20170226081A1Organic active ingredientsOrganic chemistryChemical compoundGlucose Transport Inhibition
The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
Owner:BAYER PHARMA AG
Camptothecin glycoconjugate and preparation method and application thereof
ActiveCN110423259ASolve problems in transportationAchieve anti-tumor effectEsterified saccharide compoundsOrganic active ingredientsRed blood cellCytotoxicity
The invention belongs to the technical field of medicine, and particularly relates to camptothecin glycoconjugate and a preparation method and application thereof. According to the camptothecin glycoconjugate, the camptothecin glycoconjugate is synthesized and obtained by connecting camptothecin and hexose with adipic acid as spacer. The experimental results show that the camptothecin glycoconjugate has anti-tumor effect, and has the effect of high efficiency and low toxicity compared with the camptothecin. GLUT1 is widely distributed on a blood-brain barrier and red blood cells. The experimental results show that the camptothecin glycoconjugate can be recognized and transported by the GLUT1, and the anti-tumor effect can be achieved by entering tumor cells through a GLUT1 pathway. As a kind of cytotoxicity quinoline alkaloid, the camptothecin glycoconjugate can inhibit DNA topoisomerase (TOPO I).
Owner:GUANGDONG UNIV OF TECH
Method for treating retinal degeneration disease by administering nucleolin polynucleotide or polypeptide
PendingUS20210338773A1Promoting NXNL intron retentionEasy to produceOrganic active ingredientsSenses disorderSTD - Sexually transmitted diseaseNucleotide
The present invention relates to a new method for treating a patient suffering from a retinal degenerative disease. The Inventors discovered that nucleolin (NCL) is responsible in rods of the production of the short messenger of NXNL1 gene encoding RdCVF, a crucial factor for cones survival. Thus, the administration of NCL into the retina or the overexpression of NCL in recombinant cones to be transplanted into the retina, leads to a RdCVF expression and secretion by the cones themselves in order to encourage their own survival in an autocrine manner through the BSG1 / GLUT1 complex. Thus, the invention concerns nucleolin polynucleotide or polypeptide for use in the treatment of a retinal degenerative disease in a patient in need. The invention also relates to recombinant cone overexpressing NCL for use in the treatment of a retinal degenerative disease.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
RNAi adeno-associated virus for inhibiting Slc2a1 as well as preparation and application of RNAi adeno-associated virus
ActiveCN114457045AImprove learning and memory dysfunctionReduce contentOrganic active ingredientsNervous disorderHippocampal regionInflammatory factors
The invention provides an RNAi adeno-associated virus for inhibiting Slc2a1 and a preparation method of the RNAi adeno-associated virus, wherein nucleic acid used by the RNAi is designed aiming at three interference sites on the Slc2a1. The adeno-associated virus disclosed by the invention can be used for remarkably and specifically inhibiting the expression of microglial cells Glut1; the mouse space learning and memory dysfunction caused by stress is obviously improved; the polarization of stress-induced microglial cells M1 can be inhibited, and the content of inflammatory factors in the hippocampus can be reduced; the compound is further applied to treatment of irritable learning and memory impairment, neuroinflammation and other diseases.
Owner:ACADEMY OF MILITARY MEDICAL SCI
Preparation and Application of Brain Tumor Targeting Liposomes Modified by Glucose and Triphenylphosphonium
ActiveCN113230417BPharmaceutical non-active ingredientsAntineoplastic agentsTumor targetingTriphenyl phosphonium
Owner:SICHUAN UNIV
Methods and materials for treating cancer
PendingUS20210386750A1Increased susceptibilityReduce and eliminate expressionInorganic active ingredientsTetracycline active ingredientsPhosphorylationMethyltransferase
This document provides methods and materials involved in treating mammals having cancer. For example, a mammal having a breast cancer 1 (BRCA1)-deficient cancer and / or a nicotinamide N-methyltransferase (NNMT) overexpressing cancer can be treated by administering one or more agents that can inhibit mitochondrial metabolism (e.g., one or more oxidative phosphorylation (OXPHOS) inhibitors and / or one or more inhibitors of a mitochondrial polypeptide) and / or one or more agents that can inhibit glucose transport (e.g., one or more inhibitors of a glucose transporter polypeptide such as glucose transporter 1 (GLUT1)) to the mammal. In some cases, one or more OXPHOS inhibitors can be administered to a mammal having a BRCA1-deficient cancer and / or a NNMT overexpressing cancer in combination with one or more poly(ADP-ribose) polymerase (PARP) inhibitors and / or one or more platinum compounds.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Use of saccharomyces cerevisiae ERG4 mutants for expressing mammalian glucose transporters
Owner:SANOFI AVENTIS DEUT GMBH
Methods for treating diabetes
InactiveUS20090035297A1Peptide/protein ingredientsMetabolism disorderDiabetes mellitusHexose Transporter
Owner:SCIDERA
Ginsenoside docetaxel liposome as well as preparation method and application thereof
PendingCN114712309ATargetedAnti multidrug resistanceOrganic active ingredientsPharmaceutical non-active ingredientsDocetaxelCholesterol
The invention discloses a compound ginsenoside docetaxel liposome as well as a preparation method and application thereof. The invention provides a compound ginsenoside docetaxel liposome. The compound ginsenoside docetaxel liposome is prepared from the following components in parts by mass: 8-18 parts of phospholipid, 1-1.5 parts of ginsenoside, 1 part of docetaxel and 20-35 parts of a freeze-drying protective agent, the ginsenoside docetaxel plastid does not contain one or more of cholesterol, soybean oil and sodium oleate. The ginsenoside docetaxel liposome disclosed by the invention has better active targeting property of Glut1 (Glut1); the drug effect of the ginsenoside docetaxel liposome is improved by more than two times compared with that of the conventional ginsenoside docetaxel liposome; the toxicity of the liposome is reduced by more than 1.5 times compared with that of the conventional ginsenoside docetaxel liposome and is reduced by more than 4-6 times compared with that of the conventional cholesterol docetaxel liposome; the in-vivo toxicity accumulation risk is low.
Owner:SHANGHAI GINSOME PHARMATECH CO LTD
Ginsenoside paclitaxel liposome as well as preparation method and application thereof
PendingCN114432245ATargetedAnti multidrug resistanceOrganic active ingredientsPharmaceutical non-active ingredientsCholesterolPhospholipid
The invention discloses a compound ginsenoside paclitaxel liposome as well as a preparation method and application thereof. The invention provides a compound ginsenoside paclitaxel liposome. The compound ginsenoside paclitaxel liposome is prepared from the following components in parts by mass: 8-12 parts of phospholipid, 1-1.5 parts of ginsenoside, 1 part of paclitaxel and 25-35 parts of a freeze-drying protective agent. The ginsenoside paclitaxel liposome disclosed by the invention has better active targeting property mediated by Glut1 (Glut1); the efficacy of the ginsenoside paclitaxel liposome is improved by more than two times compared with the conventional ginsenoside paclitaxel liposome; the toxicity is reduced by more than 1.5 times compared with that of the conventional ginsenoside paclitaxel lipidosome and is reduced by more than 4 times compared with that of the conventional cholesterol paclitaxel lipidosome; and the risk of toxicity accumulation in vivo does not exist.
Owner:SHANGHAI GINSOME PHARMATECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com